Apeloa Pharmaceutical Co., Ltd.

Apeloa Pharmaceutical Co., Ltd. faced a notable stock decline on July 17, 2026, despite a strong year-over-year performance. The company reported negative results for six consecutive quarters, with a significant drop in net sales and low return on capital employed, indicating challenges in its financial health.

Apeloa Pharmaceutical Co., Ltd. experienced notable stock activity today, reaching an intraday high amid a modest increase in the China Shanghai Composite. The company has shown gains over the past week and month, outperforming the index over the past year, despite facing challenges in long-term growth.

Apeloa Pharmaceutical Co., Ltd. saw a notable increase in its stock performance on June 29, 2026, contrasting with the broader market. Over the past year, the company has outperformed the Shanghai Composite, although it has faced challenges with declining performance over the longer term and consecutive quarterly losses.

Apeloa Pharmaceutical Co., Ltd. has recently experienced a change in its evaluation, reflecting a shift in its valuation metrics to a classification of very attractive. Key financial indicators show a P/E ratio of 20 and a Price to Book Value of 2.83, amidst mixed technical trends and declining growth metrics.

Apeloa Pharmaceutical Co., Ltd. has recently experienced a notable evaluation adjustment, reflecting changes in its valuation metrics and technical indicators. The company's financial metrics indicate a shift in perceived worth, while technical signals present a mixed outlook. Despite these changes, Apeloa faces challenges with declining net sales and operating profit growth.

Apeloa Pharmaceutical Co., Ltd. saw a significant rise in its stock on March 11, 2026, with an intraday high of CNY 18.83. Despite recent gains, the company faces challenges, including a 14.55% decline in net sales and a lower annual stock return compared to the China Shanghai Composite.

Apeloa Pharmaceutical Co., Ltd. experienced notable trading activity on March 6, 2026, with an intraday high of CNY 17.80. Despite a recent uptick, the company has faced challenges, including a decline in net sales and negative quarterly results, while its one-year performance lags behind the broader market.

Apeloa Pharmaceutical Co., Ltd. faced a significant stock decline, dropping 4.82% on October 22, 2025, and showing a 7.82% decrease over the month. Despite a market capitalization of CNY 18,513 million and a dividend yield of 4.48%, its long-term growth prospects remain limited.

Apeloa Pharmaceutical Co., Ltd. experienced notable stock activity on September 25, 2025, reaching an intraday high of CNY 16.96. The company has a market capitalization of CNY 18,513 million, a P/E ratio of 19.00, and a dividend yield of 4.48%, reflecting solid financial metrics.